highwaypharm.com
Article
highwaypharm.com is a recurring organization in the Astral Codex Ten archive, appearing 2 times across 2 issues between February 21, 2022 and May 08, 2023. The archive places it in contexts such as “please reach out to trevor@highwaypharm.com”; “contact me at trevor [at] highwaypharm.com”. It most often appears alongside A Clinical Introduction To Lacanian Psychoanalysis, ACX, ACX Grantee Trevor Klee.
Metadata
- Category: Organizations
- Mention count: 2
- Issue count: 2
- First seen: February 21, 2022
- Last seen: May 08, 2023
Appears In
Related Pages
-
- A Clinical Introduction To Lacanian Psychoanalysis (1 shared issues)
-
- ACX (1 shared issues)
-
- ACX Grantee Trevor Klee (1 shared issues)
-
- ACX Grants (1 shared issues)
-
- Akhorahil (1 shared issues)
-
- Astralcodexten Com (1 shared issues)
-
- Astralcodexten Com (1 shared issues)
-
- Austin (1 shared issues)
-
- Carl Cohen (1 shared issues)
-
- Cassander (1 shared issues)
-
- cats (1 shared issues)
-
- Chromocell (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
Things are progressing much faster on all fronts since we got the ACX grant. We're almost finished with computer modeling of our phase 1 trials, and are moving onto designing the phase 1 trial to answer the unanswered questions from our modeling. After that, we'll go bring our plans to the FDA for final approval. We've also doubled our team size, from 1 person + consultants to.... 2 people + consultants! I've been joined by a COO, Ken Kashkin, who has an enormous wealth of experience developing drugs on both the corporate and the research side. Most recently, he was COO of Chromocell, a ~100 person biotech company with >$30 million in revenue. Finally, we've raised about half of what we need for our minimum viable phase 1, but we're still looking for more. Ideally, we'd like to raise about $500k additional funds. If you're someone who's excited by the idea of better, safer drugs for autoimmune diseases, a rapid march to the clinic, and an ambitious plan to take on neurodegeneration, please reach out to trevor@highwaypharm.com .
Inline links: trevor@highwaypharm.com
We got the data back from our pilot trial in cats. Data looks really good and it seems like we might have a real feline stomatitis drug on our hands (more details in my blog post). Now we're looking to raise $4.5 million in SAFEs at a $25 million cap to bring the drug through trials to market. If you're interested in investing, please contact me at trevor [at] highwaypharm.com . Also if you’re not interested in investing but you’re interested in helping, I’ve put together a list of venture capitalists, angels, and potential licensing partners I’d love an introduction to.